Aktuellt
SENASTE
As usual, earnings themselves held few surprises. The operating loss was lower than expected, mainly due to trial timelines having shifted back a half year or so after the extension of the phase 1 glioblastoma trial. With DKK 39.1m in cash, Fluoguide has sufficient funding to reach data readouts in its various phase 2 trials. The next major event is the phase 2a topline from lung cancer, in Q4/22, with both the advanced glioma and head and neck cancer trial readout in H1/23.
LÄS MER
